A novel nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer

被引：1
|
作者：
Cao, S. [1 ]
Zhong, H. [2 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Pulm Med Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
73P
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [1] A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
    Cao, Shuhui
    Zhang, Yao
    Zhou, Yan
    Rong, Wenwen
    Wang, Yue
    Ling, Xuxinyi
    Zhang, Lincheng
    Li, Jingwen
    Tomita, Yusuke
    Watanabe, Satoshi
    Nakada, Takeo
    Seki, Nobuhiko
    Hida, Toyoaki
    Dermime, Said
    Zhong, Runbo
    Zhong, Hua
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (04) : 607 - +
  • [2] Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
    Britt, Alec S.
    Huang, Caitlyn
    Huang, Chao H.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
    Liu, Xiaojun
    Qiao, Liang
    FRONTIERS IN NUTRITION, 2022, 9
  • [4] Chronic Obstructive Pulmonary Disease Severity After Immune Checkpoint Inhibitor Treatment in Patients With Lung Cancer
    Szatkowski, A.
    Zhao, S.
    Henricks, J.
    Easterling, R.
    Moodabagil, M.
    Viveiros, M.
    Lopez, G.
    Li, M.
    Presley, C.
    Wei, L.
    Owen, D.
    Ho, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [5] Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
    Chen, Yan
    Hu, Junjie
    Bu, Fangfang
    Zhang, Haiping
    Fei, Ke
    Zhang, Peng
    BMC CANCER, 2020, 20 (01)
  • [6] Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer
    Giuseppe Lo Russo
    Francesco Facchinetti
    Marcello Tiseo
    Marina Chiara Garassino
    Roberto Ferrara
    Current Oncology Reports, 2020, 22
  • [7] Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
    Simone Camelliti
    Valentino Le Noci
    Francesca Bianchi
    Claudia Moscheni
    Francesca Arnaboldi
    Nicoletta Gagliano
    Andrea Balsari
    Marina Chiara Garassino
    Elda Tagliabue
    Lucia Sfondrini
    Michele Sommariva
    Journal of Experimental & Clinical Cancer Research, 39
  • [8] Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequences
    Bruyat, D.
    Girard, N.
    Penel, N.
    Heudel, P-E.
    Goncalves, A.
    Flandin, A-C. Madroszyk
    Gravis, G.
    Chanez, B.
    Collineau, B.
    Chretien, A-S.
    Beaufils, M.
    Billon, E.
    Rochigneux, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S703 - S704
  • [9] Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know
    Camelliti, Simone
    Le Noci, Valentino
    Bianchi, Francesca
    Moscheni, Claudia
    Arnaboldi, Francesca
    Gagliano, Nicoletta
    Balsari, Andrea
    Garassino, Marina Chiara
    Tagliabue, Elda
    Sfondrini, Lucia
    Sommariva, Michele
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [10] Hyperprogressive disease in cervical small cell carcinoma treated by immune checkpoint inhibitor
    Xu, Z.
    Chen, L.
    Zheng, L.
    Yang, Q.
    Chen, M.
    Wang, J.
    Zhu, G.
    Chen, Z.
    Sun, J.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1776 - 1776
12345